ArticleDiabetology & metabolic syndrome2025
Utility of type 1 diabetes genetic risk score in a non-European population: insights from an Iranian cohort.
Article in Diabetology & metabolic syndrome, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe present study aimed to investigate the efficiency of the type 1 diabetes genetic risk score (T1D GRS) in distinguishing between patients with type 1 and type 2 diabetes in Iran, an underrepresented population in genomic research.
methodsWe included 13,318 participants in the Tehran-Cardiometabolic Genetic Study (TCGS) cohort, classified into individuals without diabetes, with pre-diabetes, with type 2 diabetes, and with type 1 diabetes. Two T1D GRSs and one T2D GRS were calculated and compared between groups using the Wilcoxon test. The ability of genetic risk scores to discriminate T1D and T2D was assessed using the pROC package.
resultsBoth T1D GRSs displayed significantly higher scores in the T1D group than in other groups. Notably, T1D GRS2 effectively distinguished T1D from T2D in individuals diagnosed before age 40 (AUC = 0.8, P = 5.8e-7). This performance was even stronger for those under age 25 at diagnosis (AUC = 0.88, P = 3.2e-6). Additionally, we observed a higher median of the T1D GRS2 z-score within the T1D group and the T2D GRS z-score within the T2D group, further supporting the specificity of the tested GRSs in the Iranian population.
conclusionOur findings suggest that T1D GRS2, particularly in younger patients, shows promise for improved T1D diagnosis and potentially newborn screening in this population. This could facilitate equitable access to precision medicine approaches for individuals in the area.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.